Obesity Analyte Signatures for Personalized Treatment Selection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current obesity treatments, including diet, exercise, medications, and surgery, result in highly variable weight loss and side effects, necessitating a personalized approach to identify which intervention an obese patient is likely to respond to based on their pathophysiology.
Innovation Solution
Identifying an obesity analyte signature in a sample from a mammal, such as a blood, saliva, urine, or stool sample, to determine responsiveness to pharmacological interventions like phentermine-topiramate, lorcaserin, liraglutide, naltrexone-bupropion, or naltrexone-bupropion, tailored to specific obesity phenotypes like low satiation, low satiety, behavioral eating, or low resting energy expenditure.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current obesity treatments (diet, exercise, medications, surgery) are used, then weight loss can be achieved, but the weight loss is highly variable and side effects occur
Solution Approach 1:
The patent applies parameter changes by measuring multiple physiological parameters (metabolites, hormones, genetic markers) to characterize obesity phenotypes and select treatments accordingly. This systematic parameter assessment enables personalized treatment selection that improves weight loss consistency while reducing side effects by matching interventions to individual physiological profiles
Solution Approach 2:
The patent segments obesity into distinct phenotypic subgroups (e.g., high satiation, low satiation, high energy expenditure, low energy expenditure) based on physiological characteristics. This segmentation allows different treatment strategies to be applied to different segments of the obesity population, improving overall treatment reliability and reducing unnecessary side effects
2Reliability
If a personalized approach based on pathophysiology is implemented, then treatment responsiveness can be improved, but assessment complexity increases
Solution Approach 1:
The patent creates a universal assessment framework that uses a standardized panel of physiological markers (metabolites, hormones, genetic markers) to characterize multiple obesity phenotypes simultaneously. This multi-functional assessment system can be applied across different patient populations and treatment settings, improving treatment responsiveness while managing complexity through standardization
Solution Approach 2:
The patent implements feedback mechanisms where assessment results are used to select treatments, and treatment responses are monitored and fed back into the assessment system. This continuous feedback loop refines phenotype characterization and treatment selection over time, improving responsiveness while distributing complexity across multiple measurement and monitoring points
Data Source
AI summary
This document relates to methods and materials for assessing and/or treating obese mammals (e.g., obese humans). For example, methods and materials for using one or more interventions (e.g., one or more pharmacological interventions) to treat obesity and/or obesity-related comorbidities in a mammal (e.g., a human) identified as being likely to respond to a particular intervention (e.g., a pharmacological intervention) are provided.